The concept of a “digital twin” has moved from engineering into healthcare.

In clinical research, an AI-based digital twin refers to a computational model that simulates how an individual patient might respond under different treatment scenarios. These models draw on longitudinal data, clinical characteristics, and historical outcomes to estimate alternative trajectories.

The promise is compelling.

If sponsors can simulate likely patient outcomes, they may be able to design more efficient trials, reduce sample sizes, refine eligibility criteria, or improve endpoint sensitivity. In settings where patient populations are small or disease progression is slow, even modest efficiency gains can be meaningful.

Yet digital twins are not a universal solution.

Understanding both their potential and their limits is essential.

Where Digital Twins Add Value

Digital twins are most powerful when longitudinal disease progression is central to the trial question.

In chronic and slowly progressive diseases, modeling how symptoms or biomarkers change over time can help refine assumptions about treatment effect. If a model accurately captures expected trajectories, sponsors can design studies that are better powered to detect meaningful differences.

In rare diseases, where recruiting large numbers of patients may be impossible, digital twins offer another potential benefit. Simulated comparator arms or enriched modeling may reduce the number of participants required to demonstrate effect, provided regulators are aligned and methodological rigor is maintained.

Digital twins may also support:

• More precise stratification of patient subgroups
• Improved forecasting of event rates
• Optimization of follow-up duration
• Earlier identification of likely responders

When integrated thoughtfully into broader model-informed development strategies, these tools can strengthen decision-making before significant investment is committed.

The Data Constraint

Digital twins depend heavily on high-quality longitudinal data.

If underlying datasets are incomplete, inconsistent, or poorly harmonized, model outputs will reflect those weaknesses. Variability in real-world documentation, gaps in follow-up, and inconsistent outcome definitions can introduce bias or instability.

Comparability across datasets is another challenge. Integrating historical trial data with real-world evidence requires careful normalization. Differences in inclusion criteria, assessment frequency, and data capture methods must be addressed explicitly.

Without disciplined data engineering, digital twin outputs risk overconfidence.

The sophistication of the model cannot compensate for weak inputs.

Correlation Is Not Causation

Many AI-based digital twin models rely on deep learning methods that detect complex statistical relationships. These relationships may improve predictive performance, but they do not inherently establish causality.

In clinical research, causality matters.

Understanding whether a treatment effect is likely to persist across different populations or under alternative dosing conditions requires more than pattern recognition. Mechanistic knowledge and causal modeling approaches often need to be layered onto predictive systems.

Hybrid approaches that combine AI-driven pattern detection with traditional mechanistic modeling may offer a more balanced path forward.

The goal is not to replace established statistical frameworks, but to extend them.

Regulatory and Ethical Considerations

Digital twins introduce important governance questions.

If sample size reductions are proposed based on simulated data, how are those assumptions validated? What level of transparency is required to explain model logic to regulators? How should uncertainty be communicated?

Regulatory agencies have demonstrated openness to model-informed approaches, particularly when risk-based thinking and early engagement are applied. Clear documentation, validation strategies, and sensitivity analyses become essential components of any proposal involving digital twin methods.

Ethically, sponsors must also consider how modeling decisions affect patient access and representation. Simulation-driven efficiencies should not disproportionately exclude certain populations or narrow eligibility without strong scientific justification.

A Tool, Not a Shortcut

Digital twins hold real promise for improving efficiency and precision in clinical trial design.

They can support smarter planning, especially in therapeutic areas where progression is measurable and data are robust. They can help teams test alternative scenarios before enrolling patients. They can reduce unnecessary exposure when designed responsibly.

At the same time, they require discipline.

High-quality data, careful validation, transparent governance, and thoughtful integration with existing modeling frameworks are prerequisites. Overreliance on simulation without appropriate safeguards can create new risks.

The future of digital twins in clinical research will likely be incremental. Early use cases will focus on well-understood disease areas with strong data foundations. Confidence will grow as validation frameworks mature.

As with most AI applications in clinical trials, success will depend less on ambition and more on execution.

Digital twins are powerful tools. They are most effective when applied with clarity, restraint, and scientific rigor.

Continue the Conversation at SCOPE X

If you are exploring how AI, simulation, and model-informed approaches are shaping the future of clinical trial design, join the discussion at SCOPE X, a focused event dedicated to AI innovation in clinical trials.

SCOPE X brings together sponsors, data scientists, statisticians, and clinical leaders to examine practical applications of digital twins, predictive modeling, governance, and responsible AI deployment across the development lifecycle.